Q1 Earnings Estimate for Repligen Issued By Leerink Partnrs

Repligen Co. (NASDAQ:RGEN) – Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for Repligen in a research report issued to clients and investors on Thursday, February 20th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per share of $0.35 for the quarter, down from their prior forecast of $0.39. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.72 EPS and FY2026 earnings at $2.33 EPS.

Several other equities analysts have also issued reports on the company. Canaccord Genuity Group boosted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research report on Friday. Finally, JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Price Performance

Shares of RGEN stock opened at $164.74 on Monday. The stock has a 50-day moving average price of $155.30 and a 200 day moving average price of $148.57. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market cap of $9.23 billion, a price-to-earnings ratio of -323.02, a PEG ratio of 4.54 and a beta of 0.99. Repligen has a 12 month low of $113.50 and a 12 month high of $203.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%.

Hedge Funds Weigh In On Repligen

Institutional investors have recently modified their holdings of the business. Signaturefd LLC lifted its holdings in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen during the 4th quarter valued at about $29,000. Raiffeisen Bank International AG bought a new position in shares of Repligen during the 4th quarter valued at about $29,000. Blue Trust Inc. lifted its holdings in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV bought a new stake in Repligen in the 3rd quarter valued at approximately $37,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.